Lung Therapeutics, Inc. Email Format
Biotechnology ResearchTexas, United States11-50 Employees
In October, 2023 Lung Therapeutics was acquired by Aileron Therapeutics. Since then, Aileron has rebranded to Rein Therapeutics. Rein is now a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit https://reintx.com